Tyrosine kinase inhibitorPhase 3 trialInvestigational
Cediranib
How it works
Blocks the action of vascular endothelial growth factor receptors (VEGFRs), which are proteins that promote the growth of new blood vessels that feed cancer cells.
Cancer types
Ovarian Cancer— All patients
Efficacy
In clinical trials, cediranib has been shown to improve progression-free survival in ovarian cancer patients, with a median progression-free survival of approximately 10 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.